Auxilium Begins Trial for NeuroSpan Bridge Nerve Regeneration Device

Auxilium Technologies, a company specializing in regenerative medicine, has enrolled the first patient in its clinical trial to evaluate the NeuroSpan Bridge, an investigational device to improve nerve regeneration.

The device is a biomimetic, multi-channel scaffold that maintains linearity through the whole structure. This accelerates and guides regenerating axons to their targets on the distal end of the transected nerve.

The Neurospan-1 pivotal trial will enroll 80 patients in the U.S. It will assess the device’s performance, safety, and benefits over existing treatments. Neurospan Bridge was designed to speed nerve regeneration and nerve targeting, restoring motor and sensory function while minimizing complications and side effects like chronic pain seen in current treatments.

Auxilium said the tech is a significant step in its mission to restore lost function to those with debilitating nerve injuries to the extremities. This includes those resulting from trauma like car accidents or work-related injuries.

“We’ve spent years developing a technology with the potential to change lives, and today, we are one step closer to making that a reality,” said Jacob Koffler, Ph.D., MBA, CEO of Auxilium.

Neurospan Bridge merges the company’s expertise in regenerative science, biomaterials, and medical device manufacturing. The company also has pioneering work in microgravity bioprinting, which produced implantable medical devices on the International Space Station in February.